In breast cancer, MEOX1 is highly expressed in tumor tissues and is associated with poor overall survival, advanced tumor stage, and lymph node metastasis; Functional experiments in breast cancer cells have confirmed that MEOX1 triggers trastuzumab resistance, EMT, and self-renewal of breast cancer stem cells [19]. Here, MEOX1 is linked to breast carcinoma.